All In Biotech

Drug Trial Radar · NCT05749055

ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder

The ENCALM Trial: A Randomized, Double-blind, Placebo-controlled Monotherapy Trial to Evaluate the Efficacy and Safety of ENX-102 in Patients With Generalized Anxiety Disorder

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 252 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

252

Actual

Start

Jul 3, 2023

Primary completion

Sep 18, 2025

Study completion Sep 18, 2025

Sponsor

Lead sponsor
Engrail Therapeutics INCIndustry
Sponsor type
Industry
First posted
Mar 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Conditions

  • Generalized Anxiety Disorder

Interventions

  • ENX-102Drug

    Selective GABA-A alpha2,3,5 positive allosteric modulator

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of ENX-102 versus placebo in patients with generalized anxiety disorder (GAD)Time frame: 4 weeks

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • IMA Clinical Research Phoenix

    Phoenix, Arizona

  • Collaborative Neuroscience Research, LLC (CNS)

    Garden Grove, California

  • Sun Valley Research Center

    Imperial, California

  • Alliance Research

    Long Beach, California

  • NRC Research Institute

    Los Angeles, California

  • Excell Research, Inc.

    Oceanside, California

  • Anderson Clinical Research

    Redlands, California

  • California Neuroscience Research, LLC

    Sherman Oaks, California

  • Pacific Clinical Research Management Group

    Upland, California

  • Sunwise Clinical Research

    Walnut Creek, California

  • Mountain View Clinical Research

    Denver, Colorado

  • Vertex Clinical Research

    Clermont, Florida

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida

  • Accel Research Sites Network - Lakeland CRU

    Lakeland, Florida

  • Accel Research Sites Network - Maitland CRU

    Maitland, Florida

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida

  • CenExel iResearch, LLC

    Savannah, Georgia

  • Collective Medical Research

    Overland Park, Kansas

  • Boston Clinical Trials

    Boston, Massachusetts

  • Precise Research Centres

    Flowood, Mississippi

  • IMA Clinical Research

    Las Vegas, Nevada

  • SPRI Clinical Trials, LLC

    Brooklyn, New York

  • Neurobehavioral Research

    Cedarhurst, New York

  • Richmond Behavioral Associates

    Staten Island, New York

  • Clinical Neuroscience Solutions, Inc.

    Memphis, Tennessee

  • Austin Clinical Trials Partners

    Austin, Texas

  • FutureSearch Trials of Dallas

    Dallas, Texas

  • Baylor College of Medicine

    Houston, Texas

  • Aim Trials

    Plano, Texas

  • Grayline Research Center

    Wichita Falls, Texas

  • Alpine Research Organization

    Clinton, Utah

  • Core Clinical Research

    Everett, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.